LIGHTHOUSE identifies riboflavin 5′-monophosphate as a PPAT inhibitor
LIGHTHOUSE, a deep-learning model using protein sequence and chemical representations, nominated riboflavin 5′-monophosphate as an inhibitor of PPAT, a target without reported inhibitors in the paper. A biochemical assay measured PPAT inhibition with an IC50 of 7.5 μM, close to the model’s predicted range; the same study also tested predicted antiviral compounds in cell models.
Technology: LIGHTHOUSE (ensemble graph-based deep-learning platform)
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: LIGHTHOUSE, a deep-learning model using protein sequence and chemical representations, nominated riboflavin 5′-monophosphate as an inhibitor of PPAT, a target without reported inhibitors in the paper.
- Still unknown: The result is an in-vitro enzyme assay, not a validated anticancer treatment. The authors note LIGHTHOUSE can produce false positives; COVID-19 results were also cell-based and had no clinical evidence.
- AI role: The model scored protein–compound relationships without requiring a 3D target structure and prioritized the compound from >333,000 candidates for experimental follow-up. The authors assayed PPAT activity and confirmed inhibition in vitro.
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC9549714/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: at percentile 57 of works of the same type, year and subfield (OpenAlex work metrics, 9 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.